Adicet Bio, Inc. (ACET)
| Market Cap | 55.33M -65.1% |
| Revenue (ttm) | n/a |
| Net Income | -98.97M |
| EPS | -10.52 |
| Shares Out | 10.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 155,089 |
| Open | 4.90 |
| Previous Close | 4.89 |
| Day's Range | 4.88 - 5.17 |
| 52-Week Range | 4.80 - 17.04 |
| Beta | 1.63 |
| Analysts | Strong Buy |
| Price Target | 34.83 (+577.63%) |
| Est. Earnings | Nov 4, 2026 |
About ACET
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ACET stock is "Strong Buy." The 12-month stock price target is $34.83, which is an increase of 577.63% from the latest price.
News
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR T therapies ...
Adicet Bio price target raised to $28 from $25 at Wedbush
Wedbush analyst Robert Driscoll raised the firm’s price target on Adicet Bio (ACET) to $28 from $25 and keeps an Outperform rating on the shares. The firm notes the company…
Adicet Bio price target raised to $34 from $27 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Adicet Bio (ACET) to $34 from $27 and keeps a Buy rating on the shares after the company announced updated results for…
Adicet Bio trading halted, volatility trading pause
09:30 EDT Adicet Bio (ACET) trading halted, volatility trading pause
Adicet Bio Transcript: Study update
Prula-cel showed 50% complete renal response in lupus nephritis and 54% DORIS remission in lupus patients at 12 months, all off immunosuppressants, with a favorable safety profile and robust immune reset. A pivotal single-arm study is planned, with strong commercial potential and FDA alignment for outpatient dosing.
Adicet Bio Press release: Study update
Adicet Bio issued a press release on September 28, 2026, disclosing material business information to investors.
Adicet Bio Slides: Study update
Adicet Bio has posted slides in relation to its latest quarterly earnings report, which was published on September 28, 2026.
Adicet Bio reports data from Phase 1 study of prula-cel
Adicet Bio (ACET) announced safety and efficacy data from the Phase 1 study evaluating prulacabtagene leucel as a potential treatment for patients with systemic lupus erythematosus with or without lup...
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies ...
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies ...
Adicet data update presents attractive opportunity, says H.C. Wainwright
H.C. Wainwright reiterates a Buy rating and $27 price target on shares of Adicet Bio (ACET), telling investors in a research note that Adicet’s upcoming month-end prula-cel data update in…
Adicet Bio Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Gamma delta CAR-T therapy offers a safer, off-the-shelf alternative to alpha beta CAR-T, with comparable efficacy and outpatient administration. Major clinical data in LN and SLE is expected soon, with pivotal trials and new programs in autoimmune and oncology planned over the next 18 months.
Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies ...
Adicet Bio completes last patient visit for analysis of prula-cel in lupus
Adicet Bio (ACET) announced completion of the last patient visit for the planned Phase 1 safety and efficacy analysis of prulacabtagene leucel – prula-cel – in patients with systemic lupus…
Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies ...
Adicet Bio announces FDA clearance of IND application for ADI-212
Adicet Bio (ACET) announced that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug application for ADI-212 for the treatment of patients with metastatic castrati...
Adicet Bio Announces FDA Clearance of IND Application for ADI-212
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies ...
Adicet Bio Transcript: Canaccord Genuity's 46th Annual Growth Conference
Significant upcoming data releases are expected for allogeneic cell therapies in LN, SLE, prostate cancer, and systemic sclerosis, with the largest data set to date in LN/SLE. The lead therapy offers a well-tolerated, off-the-shelf alternative to autologous CAR T, with pivotal studies and regulatory updates forthcoming.
Adicet Bio price target lowered to $90 from $100 at Guggenheim
Guggenheim lowered the firm’s price target on Adicet Bio (ACET) to $90 from $100 and keeps a Buy rating on the shares. The firm’s lowered target reflects the company’s updated…
Adicet Bio reports Q2 EPS ($1.99), consensus ($1.64)
“At Adicet, we continue to advance prula-cel toward our next important clinical milestone, with a Phase 1 clinical update now expected in the third quarter of 2026. The additional follow-up…
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease...
Adicet Bio Quarterly report: Q2 2026
Adicet Bio has published its Q2 2026 quarterly earnings report on August 5, 2026.
Adicet Bio Earnings release: Q2 2026
Adicet Bio released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Adicet Bio Slides: Investor presentation
Adicet Bio has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.